Argireline

acetyl hexapeptide-8, acetyl hexapeptide-3 (older INCI name for the same molecule), Ac-EEMQRR-NH2, "Botox in a jar" (marketing)

Sexual health, hormones & signalling

Awaiting medical reviewEN ES DE FR PT ZH+ Follow for updates

Summary

Class: Synthetic six-amino-acid peptide (acetylated at one end, amidated at the other) modelled on the N-terminal of SNAP-25, a protein nerve endings need to release neurotransmitter
Mechanism: Proposed to compete with SNAP-25 in the "SNARE" complex, slightly reducing acetylcholine release at the nerve–muscle junction and so softening expression lines — a very mild, reversible version of what botulinum toxin does, if it penetrates far enough
Routes studied: Topical creams, serums and emulsions (0.005–10%, most products 5–10%); microneedle patches (small studies). Injection has not been studied and is not a cosmetic use
Dose range reported: Cosmetic studies: 5% and 10% formulations applied twice daily for 15–30 days; typical commercial serums 5–10% of a solution that is itself usually 0.05% peptide, so actual peptide concentrations are often around 0.0025–0.005%. No "dose" in the drug sense exists
Half-life: Not applicable; topical. Skin penetration is low — a 2015 study found very little peptide penetrating human skin in vitro, more through flexed/damaged skin
Storage: Cosmetic products: room temperature, away from heat and light, use within the period-after-opening symbol. Raw peptide powder/solution: refrigerate; solutions are relatively stable at neutral pH
Regulatory status: Permitted cosmetic ingredient worldwide; no medicinal approval anywhere; claims limited to cosmetic (appearance) rather than medical effects

Doses are as reported in studies or by the community — never recommendations.

1What it is

Argireline is the trade name for acetyl hexapeptide-8, a short synthetic peptide introduced by the Spanish cosmetic-ingredient company Lipotec (now part of Lubrizol) in the early 2000s. It copies six amino acids from the end of SNAP-25, one of the three proteins (the SNARE complex) that nerve endings use to fuse neurotransmitter vesicles with the membrane. Botulinum toxin works by chopping SNAP-25 up; Argireline was designed to get in the way of the same complex without cutting anything, giving a weak, reversible effect.

It is one of the most widely used "anti-wrinkle" peptides in skincare, often marketed alongside Snap-8, Matrixyl and copper peptides. Unlike most compounds on this site it is not injected and has never been intended for research use beyond cosmetic science; it appears here because it is frequently confused with injectable peptides and because the community sometimes asks whether it does anything at all.

2How it's thought to work

SNARE interference. in cell culture, acetyl hexapeptide-3/8 reduced calcium-triggered catecholamine release from chromaffin cells (a model for neurotransmitter release) at millimolar concentrations by competing with SNAP-25 for the SNARE complex (Blanes-Mira 2002). Less acetylcholine released at the facial muscle would mean slightly weaker contraction and shallower dynamic lines.

The penetration problem. to act it must cross the stratum corneum, epidermis and dermis to reach nerve–muscle junctions under the skin. A hexapeptide is about 900 Da and water-soluble, which argues against meaningful passive penetration; in-vitro human skin studies found penetration was very low but not zero and increased with repeated flexing (Kraeling 2015). Whether enough reaches the target to act is unresolved.

Alternative explanations. moisturising and film-forming effects of the vehicle, and possible effects on fibroblast collagen production reported in culture, may account for some of the measured improvement. Some studies in mice suggest it can also reduce collagen breakdown via catecholamine effects, but these are indirect.

Proposed: a six-amino-acid copy of part of SNAP-25, the protein a nerve ending needs to release its transmitter. In cell culture it competes with SNAP-25; whether enough reaches a facial nerve through intact skin is the open question.Schematic — not to scale

3What the research shows

Peri-orbital wrinkles (topical)

In the original industry study, 10 women applied a 10% Argireline emulsion around the eyes twice daily for 30 days; silicone-replica measurements showed wrinkle depth reduced by about 30% vs 10% with vehicle (Blanes-Mira 2002, Int J Cosmet Sci). Small, single-blind, industry-run. [1]

Independent randomised trial

In a double-blind of 60 Chinese adults, 10% acetyl hexapeptide-8 cream applied twice daily for 4 weeks reduced periorbital wrinkle roughness and depth by around 48% vs 0% in the placebo group on silicone-replica analysis, with no adverse reactions (Wang 2013, Am J Clin Dermatol). Short duration, single centre, modest size; notably not industry-funded. A follow-up from the same group reported subjective improvement in a similar design. [2]

Graded D/B (physical measurement)

Skin penetration

In-vitro diffusion through human skin found very low penetration (well under 1%) under static conditions, increasing with flexing (Kraeling 2015, Cutan Ocul Toxicol). A 2016 study using confocal Raman spectroscopy similarly found limited penetration beyond the stratum corneum. These studies are the main scientific challenge to the mechanism. [3]

Comparison with botulinum toxin

No head-to-head study exists; "topical Botox" claims are marketing. Effect sizes, where measured, are far smaller and depend on continued daily use.

Graded C/D

Microneedle and nanocarrier delivery

Studies using dissolving microneedle patches or liposomal carriers in animals or ex vivo skin report deeper delivery (various 2015–2022 papers in pharmaceutics journals). No clinical efficacy trials.

Graded D/C

Collagen and skin ageing beyond expression lines

Fibroblast culture and mouse studies suggest increased collagen I expression or reduced UV-induced wrinkles; preliminary.

4Reported side effects and interactions

Literature-reported

no adverse effects reported in the published cosmetic trials; a 2012 safety review by the Cosmetic Ingredient Review (CIR) panel did not flag toxicity concerns at cosmetic concentrations †. Skin irritation and allergic contact dermatitis are possible with any topical product and have been reported occasionally, more often attributed to other ingredients in the formulation.

Community-reported

mild stinging or redness on application (usually vehicle-related), temporary feeling of tightness or "heaviness" in treated areas, breakouts in acne-prone skin from the emulsion base; some report subtle softening of fine lines with sustained use, many report no visible change. Isolated reports of eyelid heaviness or drooping are anecdotal and unconfirmed.

Theoretical. if the peptide did penetrate well enough to meaningfully reduce neurotransmitter release, prolonged twice-daily application might in principle weaken facial muscles or affect expression in the way botulinum toxin does; current penetration data make this unlikely. Injection of cosmetic-grade Argireline is not studied and carries sterility and unknown-effect risks — it is not a cosmetic use. Pregnancy and breastfeeding: no data; topical exposure is likely negligible but untested.

Interactions. none pharmacological. Strong acids (glycolic, high-strength vitamin C) and some preservatives can destabilise peptides if mixed in the same formulation; layering in separate steps is usual advice. Occlusive or penetration-enhancing products (retinoids, microneedling devices) would increase whatever absorption occurs.

Markers researchers commonly monitor

Marker	Why it's watched
No blood or physiological markers apply to a topical cosmetic peptide; no compound-specific markers are established
Cosmetic studies track skin surface measures: wrinkle depth and roughness by silicone replica or 3D profilometry, skin elasticity (cutometer), hydration (corneometer) and standardised photography
Signs of irritation or contact dermatitis at the application site, which are the only realistic safety signal
If anyone were to inject cosmetic Argireline (not a studied use), the relevant concerns would be injection-site infection and unexpected muscle effects, and general baselines (CBC)	but this is outside its evidence base entirely.

Free for everyone. Safety information is never behind a paywall.

5Reconstitution and handling

Argireline is sold to formulators as a 0.05% aqueous solution (the "Argireline solution C" format) or as powder, and is used at 5–10% of that solution in finished products. Home formulators typically add the solution to the water phase of a serum at below 40 °C and keep the pH near neutral (5.5–7). It is not designed for with or injection; the calculator does not apply. For raw powder, dissolve in distilled water, refrigerate, and discard if cloudy.

Open in calculator, pre-loaded →

6Commonly studied alongside

Snap-8 and Matrixyl (above); palmitoyl tripeptide-1 and tetrapeptide-7 (Matrixyl 3000); copper tripeptide-1 (GHK-Cu); retinoids and vitamin C (as comparators or in layered routines); hyaluronic acid vehicles.

Informational cross-links. Not stack recommendations.

Related cosmetic peptides

Snap-8 (acetyl octapeptide-3). An eight-amino-acid extension of Argireline from the same developer, also modelled on SNAP-25 and marketed as a more potent version. The supporting evidence is an industry in-vitro study and a small cosmetic trial reporting roughly a third less wrinkle depth over 28 days †; it shares the same penetration question and has no independent controlled trial. It is commonly combined with Argireline in "expression line" serums.

Matrixyl (palmitoyl pentapeptide-4, formerly palmitoyl pentapeptide-3). A five-amino-acid fragment of collagen I (KTTKS) attached to a palmitic acid tail to improve skin penetration, developed by Sederma. Rather than acting on nerves it is a "signal peptide" that stimulates fibroblasts to produce collagen, fibronectin and glycosaminoglycans in culture, and a 12-week double-blind split-face study in 93 women reported reduced wrinkle depth and improved texture compared with vehicle (Robinson 2005, Int J Cosmet Sci, reference 6 above). It is one of the better-supported cosmetic peptides, though the evidence base is still small and largely industry-funded; its successors (Matrixyl 3000, Matrixyl Synthe'6) combine it with other signal peptides.

7Regulatory status by region

Region	Status (checked —)
United States	Permitted cosmetic ingredient (INCI: acetyl hexapeptide-8). Any claim to affect muscle or nerve function would make a product an unapproved drug under FDA rules; marketing is confined to appearance claims
European Union	Permitted cosmetic ingredient under the Cosmetics Regulation; listed in CosIng; no restrictions
United Kingdom	Same as EU (UK Cosmetics Regulation)
Australia	Permitted cosmetic ingredient; products making therapeutic claims fall under TGA
South Africa	Permitted cosmetic ingredient †
Sport (WADA)	Not relevant; not listed

8Open questions

Does enough acetyl hexapeptide-8 reach the neuromuscular junction through intact skin to act by the proposed mechanism?
Independent, longer (3–6 month) controlled trials with objective wrinkle measurement.
Whether delivery technologies (microneedle patches, carriers) change the effect or introduce the muscle-weakening risks that would come with real penetration.
Head-to-head comparison with retinoids, which have far stronger evidence for photo-ageing.

9References

1Blanes-Mira C et al. (2002). A synthetic hexapeptide (Argireline) with antiwrinkle activity. Int J Cosmet Sci. PubMed · DOI
2Wang Y et al. (2013). The anti-wrinkle efficacy of argireline, a synthetic hexapeptide, in Chinese subjects: a randomized, placebo-controlled study. Am J Clin Dermatol. PubMed · DOI
3Kraeling MEK et al. (2015). In vitro skin penetration of acetyl hexapeptide-8 from a cosmetic formulation. Cutan Ocul Toxicol. PubMed · DOI
4Gutierrez LM et al. (1997). A peptide that mimics the C-terminal sequence of SNAP-25 inhibits secretory vesicle docking in chromaffin cells. J Biol Chem. PubMed · DOI
5Lupo MP, Cole AL (2007). Cosmeceutical peptides. Dermatol Ther. PubMed · DOI
6Robinson LR et al. (2005). Topical palmitoyl pentapeptide provides improvement in photoaged human facial skin. Int J Cosmet Sci. PubMed · DOI
7Schagen SK (2017). Topical peptide treatments with effective anti-aging results. Cosmetics. DOI
8Errante F et al. (2020). Cosmeceutical peptides in the framework of sustainable wellness economy. Front Chem. PubMed · DOI

† Being confirmed by our reviewers against current sources.

10Community

forum threads →

community protocols include this →

Threads and protocols are visible to members. Joining is free.

Self-reported side effects Phase 2

Not enough data yet. 0 of the 50 members needed have logged this compound for 4+ weeks. We don't show anything below 50, so no one can be identified.

11Page history

25 Oct 2026Profile published — awaiting medical review

Licensed CC BY-NC-SA 4.0. Found an error? Report it · Editorial standards — corrections are logged here.